EV / EBITDA společnosti Inhibrx
Jaká je hodnota metriky EV / EBITDA společnosti Inhibrx?
Hodnota metriky EV / EBITDA společnosti Inhibrx, Inc. je N/A
Jaká je definice metriky EV / EBITDA?
EV/EBITDA je podniková hodnota dělená EBITDA (zisk před odečtením úroků, daní, odpisů a amortizací). Měří nákladnost akcie a používá se k porovnání společností mezi sebou častěji než P/E ratio. Měří cenu, jakou investor zaplatí za pohyb hotovosti ve společnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Inhibrx
Čemu se věnuje společnost Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Firmy s metrikou ev / ebitda podobnou společnosti Inhibrx
- Hodnota metriky EV / EBITDA společnosti Wishpond Technologies je N/A
- Hodnota metriky EV / EBITDA společnosti Future Bright je N/A
- Hodnota metriky EV / EBITDA společnosti GoldQuest Mining je N/A
- Hodnota metriky EV / EBITDA společnosti Powercell Sweden Sk ,022 je N/A
- Hodnota metriky EV / EBITDA společnosti O3 Mining je N/A
- Hodnota metriky EV / EBITDA společnosti Tijaria Polypipes je N/A
- Hodnota metriky EV / EBITDA společnosti Inhibrx je N/A
- Hodnota metriky EV / EBITDA společnosti Kidsland International je N/A
- Hodnota metriky EV / EBITDA společnosti Americas Car Mart je N/A
- Hodnota metriky EV / EBITDA společnosti Reabold Resources Plc je N/A
- Hodnota metriky EV / EBITDA společnosti Ausmex Mining je N/A
- Hodnota metriky EV / EBITDA společnosti amalphi ag je N/A
- Hodnota metriky EV / EBITDA společnosti Silver Range Resources je N/A